J&J’s Paliperidone Will Not Need Additional Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to submit its response to FDA’s “approvable” letter by the end of the month.
You may also be interested in...
J&J's Invega Will Launch In January As Follow-On To Risperdal
Paliperidone is the first atypical antipsychotic to be approved since 2003.
J&J's Invega Will Launch In January As Follow-On To Risperdal
Paliperidone is the first atypical antipsychotic to be approved since 2003.
J&J's Antipsychotic Franchise May Be "Invega"rated On Dec. 20
Risperdal follow-on's trade name is revealed; paliperidone will get a short re-review from FDA, company says.